Fourth quarter (2022-04-01 - 2022-06-30)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2022-06-30 was 88,48% (96,55%).**
Fiscal year (2021-07-01 - 2022-06-30)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2022-06-30 was 88,48% (96,55%).**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 30th of
** Solidity: Equity divided by total capital.
Highlights during the fiscal year
Fourth quarter (2022-04-01 - 2022-06-30)
- No significant highlights during the period.
Third quarter (2022-01-01 - 2022-03-31)
- No significant highlights during the period.
Second quarter (2021-10-01 - 2021-12-31)
- November -
ODI Pharma published its annual report for the fiscal year 2020/2021. -
December -
ODI Pharma held its Annual General Meeting in the office of the Company. A summary of the resolutions can be found on the Company's website (http://www.odipharma.com).
First quarter (2021-07-01 - 2021-09-30)
- July -
ODI Pharma announced that Niclas Kappelin acquired 20,000 shares inODI Pharma and that he thereby exceeded the threshold of five percent. -
August -
ODI Pharma approved the official launch of the exclusive CBD-infused skincare line kandol., which will be available online at www.kandol.net startingmid-September 2021 . -
September -
ODI Pharma announced that the official launch date of kandol. will be 1st ofOctober 2021 . The products will initially be available at www.kandol.net to customers within the EU.
Highlights after the end of the fiscal year
- No significant highlights after the end of the fiscal year.
Comments by CEO
The launch of kandol. has been one of our highlights during the last year. We are very pleased with the acceptance and interest in our products and are certain that the presence of cannabinoids in cosmetics will continue to grow over the next years. I am confident that our products are based on a disrupting formula that has the possibility to show outstanding effects. Our products were nominated for a range of awards, amongst others for the Vogue Beauty Awards 2022. Moving into a new year, we will continue to spread awareness of kandol. and hope to see the continued promotion of our products in important channels for the cosmetics industry; offline and online, with a focus on Social Media. We have completed the first phase of our business model to set the infrastructure in place in
We are continuously making progress with Project Poland - understandably, the most important aspect of our business, and we optimistically see results in the not-so-distant future. The importance of this is well understood. - We are looking forward to being able to provide Polish patients with medicine of high quality at a competitive price. We are continuously looking at the existing supply chain in
In terms of other markets of interest, we are continuously monitoring the acceptance of medicinal cannabis throughout
I want to thank our shareholders for your continued trust in
Derek Simmross
CEO,
For more information on
Derek Simmross, CEO,
E-mail: info@odipharma.com
https://news.cision.com/odi-pharma/r/odi-pharma-ab--publication-of-year-end-report-for-the-fiscal-year-2021-2022,c3620659
https://mb.cision.com/Main/19043/3620659/1619227.pdf
(c) 2022 Cision. All rights reserved., source